Too many drugs that did not lead to a cure for the disease Alzheimer’sHowever, a new study revealed an experimental drug that achieved good results on patients.
Esai and Biogen said their experimental Alzheimer’s drug slowed cognitive and functional decline in a large number of patients in the early stages of the disease.
In turn, said Ronald Petersen, director of the Alzheimer’s Research Center at the Mayo Clinic in Rochester, Minnesota, commenting on the results of a study on the new drug published late on Tuesday evening, “It is not a significant effect, but it is a positive effect.”
slows down the disease
The drug lekanmab slowed disease progression by 27 percent compared to a placebo, achieving the main goal of the study, which may give hope to patients and their families who yearn for an effective treatment.
The race to halt the deterioration of Alzheimer’s disease comes at a time when the number of Americans suffering from Alzheimer’s is expected to nearly double to 13 million by 2050, according to the Alzheimer’s Association, a volunteer health organization focused on patient care and medical research.
An Alzheimer’s patient (Archyde.com)
The Alzheimer’s Disease International, an organization that brings together global links to combat the disease, said the number might reach 139 million globally by 2050 if no effective treatment is found.
approval for marketing
Eisai, who leads the licanmab partnership program and is half in it, is seeking US Food and Drug Administration (FDA) approval on a faster-paced track, with a decision expected in early January.
Chief Executive Officer Haruo Neto told reporters in Tokyo that Eisai aims to have the drug fully approved and marketed in the United States, Europe and Japan by the end of 2023.
Alzheimer’s
Esai said the results from the study of 1,800 patients prove the long-held theory that removing accumulated stores of a protein called amyloid beta in the brains of patients with early-stage Alzheimer’s can slow the progression of the disease.
It is noteworthy that many pharmaceutical companies have not yet succeeded in finding an effective treatment for the disease that affects brain functions, and the number of patients around the world has reached regarding 55 million.
